656237-73-9Relevant articles and documents
2,3-Diaminopyridine as a platform for designing structurally unique nonpeptide bradykinin B1 receptor antagonists
Feng, Dong-Mei,Wai, Jenny M.,Kuduk, Scott D.,Ng, Christina,Murphy, Kathy L.,Ransom, Richard W.,Reiss, Duane,Chang, Raymond S.L.,Harrell, Charles M.,MacNeil, Tanya,Tang, Cuyue,Prueksaritanont, Thomayant,Freidinger, Roger M.,Pettibone, Douglas J.,Bock, Mark G.
, p. 2385 - 2388 (2005)
A novel class of 2,3-diaminopyridine bradykinin B1 receptor antagonists is disclosed. Structure-activity relationship studies (SARs) that led to compounds with significantly improved potency and pharmacokinetic properties relative to the lead compound are described.
2-(biarylalkyl)amino-3-(heterocyclylcarbonylamino)-pyridine derivatives
-
Page/Page column 14, (2010/11/30)
Compounds disclosed herein are bradykinin B1 antagonist compounds useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.